Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946174> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4361946174 abstract "<div>Abstract<p><b>Purpose:</b> We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUC<sub>ss</sub>) following multiple crizotinib 250-mg twice-daily dosing in patients with <i>ALK</i>-positive cancer.</p><p><b>Experimental Design:</b> A pharmacokinetic model was fit to data from 1,214 patients. We identified statistically significant covariates (<i>P</i> ≤ 0.001) by evaluating their effects on CL/F and V2/F and estimated their magnitudes.</p><p><b>Results:</b> Age, Eastern Cooperative Oncology Group performance status, aspartate aminotransferase (AST) levels, albumin levels, and smoking status had no effect on CL/F or V2/F. Statistically significant covariates were Asian race and female sex for CL/F and V2/F and body weight, creatinine clearance (CLcr), and total bilirubin for CL/F only. The model predicted that CL/F would be 9% lower or higher in a 40-kg or a 100-kg patient, respectively; 16% lower in patients with CLcr 30 mL/minute; 23% lower in Asians; and 11% lower in females than the reference patient (65-kg non-Asian male; baseline CLcr, 91.6 mL/minute; total bilirubin, 0.41 mg/dL). The effect of total bilirubin on CL/F was small. V2/F was 23% lower in Asians than non-Asians and females than males. Effects of all significant covariates on AUC<sub>ss</sub> were not predicted to be clinically relevant.</p><p><b>Conclusions:</b> Crizotinib at a 250-mg twice-daily starting dose appears to be appropriate for all patients irrespective of age, sex, race, body weight, mild or moderate renal impairment, or hepatic function (in the range evaluated: bilirubin ≤ 2.1 mg/dL or AST ≤124 U/L). <i>Clin Cancer Res; 22(23); 5722–8. ©2016 AACR</i>.</p></div>" @default.
- W4361946174 created "2023-04-05" @default.
- W4361946174 creator A5000548110 @default.
- W4361946174 creator A5011152885 @default.
- W4361946174 creator A5015586650 @default.
- W4361946174 creator A5031890718 @default.
- W4361946174 creator A5034894074 @default.
- W4361946174 creator A5050537391 @default.
- W4361946174 creator A5054026378 @default.
- W4361946174 creator A5061648315 @default.
- W4361946174 date "2023-03-31" @default.
- W4361946174 modified "2023-10-14" @default.
- W4361946174 title "Data from Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer" @default.
- W4361946174 doi "https://doi.org/10.1158/1078-0432.c.6526605" @default.
- W4361946174 hasPublicationYear "2023" @default.
- W4361946174 type Work @default.
- W4361946174 citedByCount "0" @default.
- W4361946174 crossrefType "posted-content" @default.
- W4361946174 hasAuthorship W4361946174A5000548110 @default.
- W4361946174 hasAuthorship W4361946174A5011152885 @default.
- W4361946174 hasAuthorship W4361946174A5015586650 @default.
- W4361946174 hasAuthorship W4361946174A5031890718 @default.
- W4361946174 hasAuthorship W4361946174A5034894074 @default.
- W4361946174 hasAuthorship W4361946174A5050537391 @default.
- W4361946174 hasAuthorship W4361946174A5054026378 @default.
- W4361946174 hasAuthorship W4361946174A5061648315 @default.
- W4361946174 hasConcept C112705442 @default.
- W4361946174 hasConcept C126322002 @default.
- W4361946174 hasConcept C126894567 @default.
- W4361946174 hasConcept C139254425 @default.
- W4361946174 hasConcept C159641895 @default.
- W4361946174 hasConcept C2776232967 @default.
- W4361946174 hasConcept C2776256026 @default.
- W4361946174 hasConcept C2777513400 @default.
- W4361946174 hasConcept C2779422266 @default.
- W4361946174 hasConcept C2780306776 @default.
- W4361946174 hasConcept C71924100 @default.
- W4361946174 hasConcept C90924648 @default.
- W4361946174 hasConceptScore W4361946174C112705442 @default.
- W4361946174 hasConceptScore W4361946174C126322002 @default.
- W4361946174 hasConceptScore W4361946174C126894567 @default.
- W4361946174 hasConceptScore W4361946174C139254425 @default.
- W4361946174 hasConceptScore W4361946174C159641895 @default.
- W4361946174 hasConceptScore W4361946174C2776232967 @default.
- W4361946174 hasConceptScore W4361946174C2776256026 @default.
- W4361946174 hasConceptScore W4361946174C2777513400 @default.
- W4361946174 hasConceptScore W4361946174C2779422266 @default.
- W4361946174 hasConceptScore W4361946174C2780306776 @default.
- W4361946174 hasConceptScore W4361946174C71924100 @default.
- W4361946174 hasConceptScore W4361946174C90924648 @default.
- W4361946174 hasLocation W43619461741 @default.
- W4361946174 hasOpenAccess W4361946174 @default.
- W4361946174 hasPrimaryLocation W43619461741 @default.
- W4361946174 hasRelatedWork W1542806679 @default.
- W4361946174 hasRelatedWork W1544023406 @default.
- W4361946174 hasRelatedWork W1974378936 @default.
- W4361946174 hasRelatedWork W2012297418 @default.
- W4361946174 hasRelatedWork W2044398229 @default.
- W4361946174 hasRelatedWork W2046899919 @default.
- W4361946174 hasRelatedWork W2072241133 @default.
- W4361946174 hasRelatedWork W2112758375 @default.
- W4361946174 hasRelatedWork W2400700397 @default.
- W4361946174 hasRelatedWork W393698729 @default.
- W4361946174 isParatext "false" @default.
- W4361946174 isRetracted "false" @default.
- W4361946174 workType "article" @default.